查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947986

PNH治療市場按治療類型、作用機制、給藥途徑、最終用戶和分銷管道分類，全球預測，2026-2032年

Treatment of PNH Market by Treatment Type, Mechanism Of Action, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，陣發性夜間血紅蛋白尿症 (PNH) 治療市場價值將達到 15.7 億美元，到 2026 年將成長至 16.4 億美元，到 2032 年將達到 20.8 億美元，複合年成長率為 4.08%。

關鍵市場統計數據
基準年 2025 15.7億美元
預計年份：2026年 16.4億美元
預測年份 2032 20.8億美元
複合年成長率 (%) 4.08%

一個簡潔的背景框架，闡述了影響當代陣發性睡眠性血紅蛋白尿症（PNH）治療決策的臨床複雜性和不斷變化的治療重點。

陣發性睡眠性血尿症(PNH) 仍然是一種臨床表現複雜的血液系統疾病，其特徵是補體依賴性血管內溶血、骨髓衰竭風險以及血栓併發症，這些因素導致高發病率和治療複雜性。過去十年，治療進展已使 PNH 的治療從以支持治療為主轉變為以標靶補體抑制劑治療為主，從根本上改變了患者的病程和臨床決策。本文整合了目前的臨床範式，重點介紹了一類重新定義治療目標的治療藥物，並提出了醫療保健相關人員現在必須回答的策略性問題，以最佳化治療效果並維持醫療服務的可及性。

分子創新和基於真實世界證據的醫學重塑如何共同重塑陣發性睡眠性血紅蛋白尿症（PNH）的治療方案、治療模式和實證策略。

受分子創新、新型給藥方式以及相關人員不斷變化的期望驅動，陣發性睡眠性血紅蛋白尿症 (PNH) 的治療格局發生了變革性變化。長效 C5 抑制劑的出現降低了輸注頻率，並重塑了輸液中心的利用模式；而近端補體途徑抑制劑則引入了新的作用機制，帶來了不同的療效和安全性權衡。這些臨床進展迫使臨床醫生和醫療系統重新評估治療流程，將焦點從單純的生化終點轉向患者功能、血紅蛋白穩定性以及輸血獨立性等綜合指標。

關稅趨勢變化對生物製藥供應鏈、籌資策略和醫療保健連續性基礎設施的影響（至2025年）

到2025年，一系列政策變化和貿易趨勢為生物製藥生產、分銷和臨床應用領域的利益相關相關人員帶來了新的財務和營運挑戰。影響生物製藥組件、一次性醫療設備和低溫運輸物流材料進口的關稅調整，促使供應商重新檢視其策略、庫存緩衝和契約製造協議。因此，製造商和經銷商正在重組其供應鏈，以降低關稅波動帶來的風險，加速區域採購，並實現契約製造合作夥伴的多元化，從而保障依賴先進生物療法的患者的治療連續性。

如何透過整合治療類型、作用機制、給藥途徑、最終用戶和分銷管道等因素進行細分，從而驅動差異化的臨床和營運策略

分段分析為評估陣發性睡眠性血紅蛋白尿症 (PNH) 治療的療效、治療途徑和運作需求建立了框架。根據治療類型，Eculizumab單抗、培塞他考普蘭和Ravulizumab單抗之間的臨床差異會影響到針對特異性機制的療效、給藥間隔和患者選擇的決策，並且每種治療方法都有其獨特的監測和支持需求。根據作用機制，C3 抑制劑與 C5 抑制劑在溶血控制、感染風險以及潛在的聯合或序貫給藥策略方面具有重要意義。作用機制的選擇決定了實驗室監測的頻率和預防性疫苗接種策略。

區域監管、報銷和醫療服務趨勢將對全球陣發性睡眠性血紅蛋白尿症（PNH）治療領域的治療方案採納和獲取策略產生決定性影響。

區域趨勢影響PNH治療實施的關鍵，包括監管時間表、報銷環境和醫療服務能力。在美洲，完善的法規結構和先進的專科醫療網路促進了新型治療方法的快速應用，而支付方的談判和醫療管理模式則對治療使用模式和獲取途徑產生重大影響。尤其在美國，基於價值的合約和專科藥房合作日益受到重視，這影響著患者接受輸液和居家治療的方式和地點。

藥物研發者的策略重點與競爭動態影響PNH治療產品的差異化、證據產生與取得途徑。

大型生物製藥公司之間的競爭以生命週期最佳化、產品組合差異化和策略聯盟為特徵。長期從事C5抑制劑研發的公司持續專注於製劑改進、延長給藥間隔策略以及完善患者支持體系，以維持其臨床相關性。同時，專注於近端補體抑制的新興參與企業則基於特定的臨床終點，宣稱其產品具有顯著的療效和生活品質改善。每家公司都在進行不同的臨床項目，包括頭對頭試驗、治療方案轉換的療效評估以及聯合治療，旨在為臨床醫生明確治療順序。

為業界領導者提供切實可行的臨床、商業和供應鏈建議，以增強醫療服務可近性、累積實證醫學證據並提供以患者為中心的醫療服務。

行業領導者應倡導臨床、商業和營運方面的協作模式，以最大限度地改善患者療效並確保患者可及性。首先，應優先制定實證策略，收集長期功能性療效和醫療資源利用情況，以補充關鍵性試驗結果。這些數據將有助於加強健保報銷談判，並支持差異化的價值提案。其次，應最佳化即時照護模式，盡可能投資於家庭給藥的培訓和基礎設施建設，同時保持強大的輸液中心能力，以滿足需要靜脈輸液治療的患者的需求。這種雙管齊下的策略將減少系統瓶頸，並擴大患者的選擇範圍。

一種結合嚴謹的臨床證據審查、專家訪談和檢驗的調查方法，旨在為實際研究結果提供支持。

調查方法結合了對同行評審文獻、監管文件和臨床試驗註冊庫的系統性回顧，以及結構化的專家訪談和諮詢，以建立強力的證據基礎。臨床資料提取優先考慮隨機對照試驗、長期擴展研究和高品質觀察性隊列研究，以了解不同治療層級的療效、安全性和療效持久性。研究人員審查了監管標籤和指導文件，以確定核准的適應症、給藥方案和安全措施，同時檢索了藥物警戒資料庫，以分析與補體抑制相關的訊號檢測和不利事件模式。

概述目前陣發性睡眠性血紅蛋白尿症 (PNH) 治療現狀，整合臨床創新、營運韌性和實證准入策略

這項綜合分析表明，目前陣發性睡眠性血紅蛋白尿症 (PNH) 的治療環境日益多樣化，操作也更加複雜，這主要受多種作用機制、替代給藥途徑以及不斷變化的供應鏈因素的影響。治療方案的選擇不僅取決於溶血療效，還取決於影響患者體驗、現場可行性以及長期安全性監測的因素。不同地區的法規和報銷制度差異，使得個人化的准入策略勢在必行；而與關稅相關的供應鏈壓力，則進一步凸顯了穩健的採購和生產方式的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法的PNH治療市場

  • Eculizumab
  • 培塞他可普蘭
  • Ravulizumab

9. 依作用機轉分類的陣發性睡眠性血紅素尿症（PNH）治療市場

  • C3抑制劑
  • C5抑制劑

10. 按給藥途徑分類的 PNH 治療市場

  • 靜脈注射
  • 口服
  • 皮下注射

第11章 按最終用戶分類的 PNH 治療市場

  • 居家醫療環境
  • 醫院
  • 專科診所

第12章 按分銷管道分類的 PNH 治療市場

  • 網路藥房
  • 線下藥房

第13章 按地區分類的PNH治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的 PNH 治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國陣發性睡眠性血紅素尿症（PNH）治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 美國陣發性夜間血紅素尿症（PNH）治療市場

第17章 中國陣發性睡眠性血紅素尿症（PNH）治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Biocryst Pharmaceuticals Inc.
  • BioCryst Pharmaceuticals Inc.
  • Bristol Myers Squibb Company
  • Gilead Sciences Inc.
  • Ionis Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ra Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sobi Swedish Orphan Biovitrum AB
Product Code: MRR-4F7A6D4FB6C5

The Treatment of PNH Market was valued at USD 1.57 billion in 2025 and is projected to grow to USD 1.64 billion in 2026, with a CAGR of 4.08%, reaching USD 2.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.57 billion
Estimated Year [2026] USD 1.64 billion
Forecast Year [2032] USD 2.08 billion
CAGR (%) 4.08%

Concise contextual framing of clinical complexity and evolving therapeutic priorities that shape contemporary PNH treatment decision-making

Paroxysmal nocturnal hemoglobinuria remains a clinically complex hematologic disorder defined by complement-mediated intravascular hemolysis, bone marrow failure risk, and thrombotic complications that drive high morbidity and care complexity. Over the past decade therapeutic advances have shifted PNH from a supportive-care focus toward targeted complement inhibition, fundamentally changing patient trajectories and clinical decision-making. This introduction synthesizes the contemporary clinical paradigm, highlights the therapeutic classes that have redefined treatment goals, and frames the strategic questions healthcare stakeholders must now answer to optimize outcomes and sustain access.

Clinicians increasingly balance efficacy in hemolysis control with durability of response, administration burden, and safety considerations such as infection risk and breakthrough hemolysis. Meanwhile, payers and providers must reconcile increasingly sophisticated therapeutic options with systems-level constraints including infusion capacity, home-care viability, and specialty pharmacy networks. Patients are more informed and engaged than ever, prioritizing treatment convenience and quality-of-life improvements in addition to biological efficacy. This introduction establishes the context for the following analysis by clarifying the clinical, commercial, and operational drivers that will determine how treatment paradigms continue to evolve.

How molecular innovation and real-world evidence-driven care redesign are jointly reshaping treatment selection, delivery models, and evidence strategies across PNH

The landscape for PNH treatment has experienced transformative shifts driven by molecular innovation, novel delivery formats, and evolving stakeholder expectations. The emergence of long-acting C5 inhibitors has reduced infusion frequency and reshaped infusion center utilization, while proximal complement blockade has introduced alternative mechanisms with distinct efficacy and safety trade-offs. These clinical advances have forced clinicians and health systems to re-evaluate treatment algorithms, shifting attention from purely biochemical endpoints to integrated measures of patient function, hemoglobin stability, and transfusion independence.

Concurrently, the commercial environment has adapted; specialty pharmacy models, home infusion services, and bundled care pathways are being redesigned to accommodate both frequent-dosing subcutaneous options and extended-interval intravenous therapies. Regulatory pathways and labeling updates have accelerated lifecycle management strategies, prompting manufacturers to prioritize formulation innovation and patient support offerings. In addition, the increasing role of real-world evidence to demonstrate value and inform reimbursement has catalyzed new approaches to evidence generation, including registries and pragmatic studies that capture long-term safety and functional outcomes. The net effect is a treatment ecosystem that is more patient-centered, more diverse in therapeutic choice, and more operationally complex than in prior eras.

Implications of evolving tariff dynamics on biologics supply chains, procurement strategies, and continuity of care infrastructure through 2025

Policy changes and trade dynamics introduced in the lead-up to 2025 have created a new set of financial and operational considerations for stakeholders involved in biologics manufacturing, distribution, and clinical delivery. Tariff-related adjustments affecting imports of biologic components, single-use medical devices, and cold-chain logistics materials have translated into reassessments of supplier strategies, inventory buffering, and contract manufacturing arrangements. As a result, manufacturers and distributors have reconfigured supply chains to reduce exposure to tariff volatility, accelerate regional sourcing, and diversify contract manufacturing partners to protect continuity of care for patients reliant on high-acuity biologic therapies.

Healthcare providers and payers have likewise faced secondary impacts, including altered procurement costs for infusion supplies and ancillary disposables, shifted budgetary allocations for specialty pharmacy inventory, and increased emphasis on home-care models that reduce reliance on centralized infusion capacity. In response, some organizations have accelerated investments in domestic manufacturing capabilities and cold-chain resilience, while others have pursued procurement consortia to stabilize pricing and supply commitments. Importantly, these strategic shifts have underscored the value of transparent supply agreements and early engagement with logistics partners, since maintaining uninterrupted access to complement inhibitors is critical for preventing clinical decompensation in patients with PNH.

How integrated segmentation across treatment type, mechanism, administration route, end-user, and distribution channel drives differentiated clinical and operational strategies

Segmentation creates the framework through which therapeutic value, access pathways, and operational needs are evaluated for PNH treatments. Based on treatment type, the clinical differentiation among Eculizumab, Pegcetacoplan, and Ravulizumab informs decisions around mechanism-specific efficacy, dosing cadence, and patient selection, with each therapy presenting distinct monitoring and support requirements. Based on mechanism of action, the contrast between C3 inhibitors and C5 inhibitors has important implications for hemolysis control, infection risk profiles, and potential combination or sequential strategies; mechanism choice shapes laboratory monitoring frequency and prophylactic vaccination strategies.

Based on route of administration, the distribution of intravenous, oral, and subcutaneous options dictates site-of-care considerations, homecare feasibility, and specialty pharmacy engagement; intravenous therapies require infusion infrastructure, whereas subcutaneous formulations can expand home-based care and improve patient convenience. Based on end user, the needs of home care settings are different from hospitals and specialty clinics in terms of training, cold-chain management, and emergency backup plans, which in turn influence payer contracting and reimbursement coding. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each introduce unique inventory management, prior authorization workflows, and patient adherence support models that must be coordinated to ensure seamless treatment initiation and ongoing access.

Understanding these segmentation layers together enables stakeholders to align clinical pathways with operational capabilities, design appropriate patient support services, and prioritize investments in supply chain and distribution models that best match their patient populations and delivery contexts.

Regional regulatory, reimbursement, and care delivery dynamics that critically influence therapeutic adoption and access strategies across global PNH landscapes

Regional dynamics shape regulatory timelines, reimbursement environments, and care delivery capacities that are central to PNH treatment implementation. In the Americas, established regulatory frameworks and advanced specialty care networks facilitate rapid adoption of novel therapies, while payer negotiations and managed care mechanisms strongly influence utilization patterns and access pathways. The United States in particular has seen increased attention to value-based contracting and specialty pharmacy integration, which affects where and how patients receive infusions or home-administered therapies.

In Europe, Middle East & Africa, heterogeneity in national health systems and reimbursement approaches creates variable access landscapes that require localized market access strategies, including early engagement with health technology assessment bodies and tailored real-world evidence generation. Providers in these regions often balance centralized hospital-based infusion services with growing capabilities for homecare and outpatient delivery. In Asia-Pacific, the expansion of specialty care capacity, investments in domestic biomanufacturing, and evolving regulatory harmonization are enabling improved availability of advanced therapies, even as payer coverage and affordability remain key determinants of uptake. Across all regions, local clinical practices, vaccination protocols, and infection surveillance norms intersect with therapeutic selection and monitoring approaches, necessitating region-specific implementation plans and evidence packages.

Strategic priorities and competitive maneuvers among developers that shape product differentiation, evidence generation, and access pathways for PNH therapies

Competitive dynamics among leading biopharmaceutical organizations have been characterized by lifecycle optimization, portfolio differentiation, and strategic partnerships. The established sponsors of long-standing C5 inhibitors continue to focus on formulation improvements, extended-interval dosing strategies, and patient support frameworks to sustain clinical relevance, while newer entrants specializing in proximal complement blockade emphasize distinct efficacy and quality-of-life claims backed by targeted clinical endpoints. Companies are advancing a mix of clinical programs that evaluate head-to-head performance, switching outcomes, and combination approaches to clarify therapeutic sequencing for clinicians.

Commercial strategies reveal a dual focus on enhancing patient convenience through alternative routes of administration and on demonstrating downstream economic benefits through reduced transfusion needs, fewer thrombotic events, and lower acute-care utilization. Partnerships with specialty pharmacy providers and home infusion services are being used to expand access and streamline logistics. In parallel, some companies are investing in real-world evidence platforms and patient registries to document long-term outcomes and safety, thereby strengthening reimbursement dossiers and payer confidence. Intellectual property management, manufacturing scale-up, and strategic pricing agreements remain central themes as organizations seek to balance innovation incentives with broad patient access.

Practical clinical, commercial, and supply chain recommendations that industry leaders can implement to strengthen access, evidence generation, and patient-centric delivery

Industry leaders should pursue coordinated clinical, commercial, and operational actions to maximize patient outcomes and safeguard access. First, prioritize evidence-generation strategies that capture longitudinal functional outcomes and health resource utilization to complement pivotal trial results. These data will strengthen reimbursement discussions and support differentiated value propositions. Next, optimize site-of-care models by investing in training and infrastructure for home administration where feasible while maintaining robust infusion-center capabilities for patients requiring intravenous therapy; this dual approach reduces system bottlenecks and enhances patient choice.

Additionally, de-risk supply chains by diversifying suppliers, expanding regional manufacturing partnerships, and implementing inventory contingency plans to maintain continuity of biologic supply. Engage early and constructively with payers to design contracting arrangements that align incentives around clinical outcomes, including potential performance-based elements tied to transfusion independence or reduction in thrombotic events. Finally, deepen patient support services-education, adherence programs, and financial navigation-to reduce barriers to initiation and persistence, and integrate real-world evidence collection into these touchpoints to continuously validate long-term benefit and safety in heterogeneous patient populations.

Methodological approach combining rigorous clinical evidence review with expert interviews and triangulated validation to underpin actionable insights

The research methodology combined systematic review of peer-reviewed literature, regulatory documentation, and clinical trial registries with structured expert interviews and advisory consultations to produce a robust evidence base. Clinical data extraction prioritized randomized trials, long-term extension studies, and high-quality observational cohorts to capture efficacy, safety, and durability of response across therapeutic classes. Regulatory labeling and guidance documents were reviewed to map authorized indications, dosing regimens, and safety mitigations, while pharmacovigilance databases were examined for signal detection and adverse-event patterns relevant to complement inhibition.

Primary research included interviews with hematologists, specialty pharmacists, payer representatives, and home-care providers to validate operational assumptions and identify emerging practice patterns. Data triangulation techniques were applied to reconcile discrepancies between published evidence, expert opinion, and administrative workflows. All findings underwent quality assurance reviews, including cross-validation by clinical authors and methodological auditors, to ensure internal consistency and the highest standards of analytical rigor. Where applicable, sensitivity checks were performed on operational parameters and supply-chain scenarios to test the robustness of strategic implications derived from the evidence.

Synthesis of clinical innovation, operational resilience, and evidence-driven access strategies that summarize the contemporary state of PNH treatment

The collective analysis highlights a therapy landscape for PNH that is more diverse and operationally nuanced than ever, driven by differentiated mechanisms of action, alternative administration routes, and evolving supply-chain considerations. Treatment selection is now informed not only by hemolytic control but by factors affecting patient experience, site-of-care feasibility, and long-term safety monitoring. Regional differences in regulatory and reimbursement frameworks require tailored access strategies, and tariff-related supply-chain pressures have reinforced the need for resilient procurement and manufacturing approaches.

For stakeholders across clinical development, commercial operations, and healthcare delivery, the imperative is clear: integrate robust evidence generation with pragmatic logistics planning and patient-centric support models. Doing so will enable better-aligned therapeutic choices, smoother transitions between care settings, and sustained access. The outlook for PNH management is one of continued clinical innovation coupled with increasing emphasis on multidisciplinary systems that translate biological efficacy into durable, real-world patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Treatment of PNH Market, by Treatment Type

  • 8.1. Eculizumab
  • 8.2. Pegcetacoplan
  • 8.3. Ravulizumab

9. Treatment of PNH Market, by Mechanism Of Action

  • 9.1. C3 Inhibitor
  • 9.2. C5 Inhibitor

10. Treatment of PNH Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Treatment of PNH Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Treatment of PNH Market, by Distribution Channel

  • 12.1. Online Pharmacy
  • 12.2. Offline Pharmacy

13. Treatment of PNH Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Treatment of PNH Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Treatment of PNH Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Treatment of PNH Market

17. China Treatment of PNH Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alexion Pharmaceuticals Inc.
  • 18.7. Alnylam Pharmaceuticals Inc.
  • 18.8. Amgen Inc.
  • 18.9. Apellis Pharmaceuticals Inc.
  • 18.10. Astellas Pharma Inc.
  • 18.11. Biocryst Pharmaceuticals Inc.
  • 18.12. BioCryst Pharmaceuticals Inc.
  • 18.13. Bristol Myers Squibb Company
  • 18.14. Gilead Sciences Inc.
  • 18.15. Ionis Pharmaceuticals Inc.
  • 18.16. Johnson & Johnson
  • 18.17. Merck & Co. Inc.
  • 18.18. Novartis AG
  • 18.19. Pfizer Inc.
  • 18.20. Ra Pharmaceuticals Inc.
  • 18.21. Regeneron Pharmaceuticals Inc.
  • 18.22. Roche Holding AG
  • 18.23. Sanofi S.A.
  • 18.24. Sobi Swedish Orphan Biovitrum AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TREATMENT OF PNH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TREATMENT OF PNH MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TREATMENT OF PNH MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TREATMENT OF PNH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TREATMENT OF PNH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TREATMENT OF PNH MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TREATMENT OF PNH MARKET SIZE, BY PEGCETACOPLAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TREATMENT OF PNH MARKET SIZE, BY PEGCETACOPLAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C3 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C3 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C3 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C5 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C5 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C5 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TREATMENT OF PNH MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TREATMENT OF PNH MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TREATMENT OF PNH MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TREATMENT OF PNH MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TREATMENT OF PNH MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TREATMENT OF PNH MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TREATMENT OF PNH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS TREATMENT OF PNH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TREATMENT OF PNH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 105. GCC TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 123. G7 TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. NATO TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA TREATMENT OF PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)